Regeneron Pharmaceuticals, Inc. REGN obtained FDA approval for linvoseltamab-gcpt for the treatment of relapsed or refractory ...

Given the advantages over its rivals, Regeneron is hopeful its bispecific antibody will become the new standard of care for ...

A B-cell maturation antigen (BCMA)-directed bispecific antibody, linvoseltamab is indicated for adult patients who have ...

Presenter: Ivor Elrifi, CEO of Tiziana Life Sciences Presentation Title: Treatment of Neuroinflammation with Intranasal Foralumab Location : Boston Convention & Exhibition Center, Boston, MA ...

Tiziana Life Sciences, Ltd. announced progress in treating moderate Alzheimer's disease with its lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody. This development ...

A nasal spray, referred to as nasal anti-CD3, could be the first FDA-approved treatment for traumatic brain injury, or TBI, that can be easily administered with no serious side effects, the ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 22, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Publication title: "Nasal anti-CD3 monoclonal antibody ameliorates traumatic brain injury, enhances microglial phagocytosis and reduces neuroinflammation via IL-10-dependent Treg-microglia crosstalk” ...

NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Over the years, several CD3 antibodies and anti-CD3 antibodies have been developed to modulate CD3 activity, resulting in a dynamic market with unexplored potential.